Drugs / DPOC-4088
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01347203 | Apr → Jun 2011 | venous thromboembolism | Diakron Pharmaceuticals | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT01647620 Comparator | Feb → Sep 2012 | venous thromboembolism | Diakron Pharmaceuticals | Terminated | No outcome recorded Stop: Business |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DPOC-4088 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01347203 ↗ |
| Known as | DP-4088 | ChEMBL registry synonym — accepted as the source's own label CHEMBL30054 ↗ |
| Action | Inhibit | “ability of DPOC-4088 to inhibit thrombin activity” NCT01347203 ↗ |
| Modality | Small molecule | — CHEMBL30054 ↗ |
| Route | Oral | “single oral dose of DPOC-4088” NCT01347203 ↗ |